We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · October 01, 2020

Composite Type 2 Biomarker Strategy vs a Symptom Risk–Based Algorithm to Adjust Corticosteroid Dose in Patients With Severe Asthma

The Lancet Respiratory Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Composite Type-2 Biomarker Strategy Versus a Symptom-Risk-Based Algorithm to Adjust Corticosteroid Dose in Patients With Severe Asthma: A Multicentre, Single-Blind, Parallel Group, Randomised Controlled Trial
Lancet Respir Med 2020 Sep 07;[EPub Ahead of Print], LG Heaney, J Busby, CE Hanratty, R Djukanovic, A Woodcock, SM Walker, TC Hardman, JR Arron, DF Choy, P Bradding, CE Brightling, R Chaudhuri, DC Cowan, AH Mansur, SJ Fowler, RM Niven, PH Howarth, JL Lordan, A Menzies-Gow, TW Harrison, DS Robinson, CTJ Holweg, JG Matthews, ID Pavord

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading